Evolus, Inc. (EOLS) Fair Value 2026

EOLS · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.2 /10

32 fundamental signals · 2 models active

Value Trap Risk

LOW (32/100)

Quick Summary — As of 2026-08-28, Evolus, Inc. (EOLS) trades at $8.88, versus a $4.13 median fair value across its 2 active models — 53.5% below the current price. QOC: 6.2/10. Value Trap Risk: 32/100 (LOW). 2/13 models active.

Key Facts

Ticker
EOLS
Price
$8.88
Quality Score
6.2/10
Value Trap Risk
32/100
Models Active
2/13
Last Updated
Strength: 2 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Evolus, Inc. (EOLS) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Evolus, Inc. (EOLS) appears overvalued as of : the median of 2 independent fair value estimates is $4.13, 53.5% below the current price of $8.88. Estimates range from $2.15 to $6.11. EOLS scores 6.2/10 on fundamental quality and 32/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. EOLS’s -53.5% gap is wider than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -8.3%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Evolus, Inc. Stock in 2026? →

What Fair Value Does Each Model Give EOLS?

2 Intrinsic Value Models vs. Current Price ($8.88)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Medium Conviction
 $6.11 -31.2%
Option-Based · Medium Conviction
 $2.15 -75.7%

All Models Active

All 2 models are displayed above.

What Is Evolus, Inc. (EOLS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Evolus, Inc.'s intrinsic value is estimated at $4.13, suggesting the stock is overvalued at its current price of $8.88. With 2 out of 2 models flagging downside (-53.5% vs price), the market may be pricing in unsustainable growth. Notably, Regime Cross sees the most upside at -31.2% (fair value: $6.11), while PWERM is the most conservative at -75.7% ($2.15). The spread between these extremes — +44.6% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About EOLS?

2 of 13 models are currently active for EOLS. All 2 active models suggest the stock trades above fair value. Taken together, their median fair value for EOLS is $4.13 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does EOLS Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, EOLS ranks #49 by Quality of Company score. CirclFi's QOC score of 6.2/10 evaluates 32 fundamental signals. A score of 6.2 indicates above-average quality.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

Within the Drug Manufacturers - Specialty & Generic space, Evolus, Inc. competes in an environment where biosimilar competition timeline often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is EOLS a Value Trap?

CirclFi's Value Trap algorithm assigns EOLS a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Evolus, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Evolus, Inc. is rated at 6.2/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

The gap between the most bullish and bearish model spans +44.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every EOLS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across EOLS's 2 active models, average confidence is 39%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Evolus, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

EVOEvotec SEQOC 6.2SCYXSCYNEXIS, Inc.QOC 6.1DERMJourney Medical CorporationQOC 6.2AYTUAytu BioPharma, Inc.QOC 6.1TXMDTherapeuticsMD, Inc.QOC 6.2INCRInterCure Ltd.QOC 6.1NTRRNeutra Corp.QOC 5.1CTTHCTT Pharmaceutical Holdings, Inc.QOC 3.3HIMSHims & Hers Health, Inc.QOC 7.9UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: EVO · SCYX · DERM · AYTU · TXMD · INCR · NTRR · CTTH · HIMS · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to EOLS?

7 companies across all industries closest to EOLS’s Quality of Company score of 6.2/10.

PPHCPublic Policy Holding Company, Inc.QOC 6.2PHUNPhunware, Inc.QOC 6.2DTILPrecision BioSciences, Inc.QOC 6.2EQHEquitable Holdings, Inc.QOC 6.2GRALGRAIL, Inc.QOC 6.2RGPResources Connection, Inc.QOC 6.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: PPHC · PHUN · DTIL · EQH · GRAL · RGP · NVDA

Where Does EOLS Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

EOLS is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Evolus, Inc.’s Valuation?

What is Evolus, Inc.'s intrinsic value in 2026?

CirclFi puts Evolus, Inc. (EOLS)'s intrinsic value at $4.13 — the median of 2 independent model estimates as of 2026-08-28, ranging from $2.15 to $6.11. The Quality of Company score is 6.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is EOLS overvalued or undervalued right now?

At $8.88, 0 of 2 active models suggest EOLS may be undervalued, while 2 indicate potential overvaluation. The median of all 2 fair value estimates is $4.13, 53.5% below the current price of $8.88 — a consensus view that EOLS is overvalued. The assessment depends on which methodology best fits Evolus, Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 6.2 mean for EOLS?

Evolus, Inc.'s QOC of 6.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on EOLS?

CirclFi analyzes EOLS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is EOLS a value trap in 2026?

Evolus, Inc.'s Value Trap score is 32/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Evolus, Inc. (EOLS) has a median fair value of $4.13 — 53.5% below the current price of $8.88 — as of 2026-08-28.” Source: circlfi.com/stock/EOLS/ · Methodology
Primary sources for this EOLS valuation
  • Financial statements: Evolus, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001570562) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for EOLS as of ; valuations recomputed .